The biotechnology company’s drug for treating hives in adults has been granted an expanded indication by the European Commission to treat children and adolescents.
On Oct. 26, 2017, Shire announced that the European Commission granted approval of Firazyr (icatibant injection) for treating hereditary angioedema (HAE) attacks, or hives, in adolescents and children aged two years and older. The drug will be available for use in pediatric patients in Europe beginning in the fourth quarter of 2017.
The anti-inflammatory drug, which was previously only approved for adults with HAE, has been approved in the European Union since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency. HAE is a rare genetic disease characterized by recurrent attacks of localized oedema (swelling), and can cause life-threatening attacks when upper airways are obstructed.
“Due to the unpredictable and debilitating nature of HAE attacks, children living with the condition can benefit from having a new treatment option that can provide symptomatic relief of acute HAE attacks with a subcutaneous injection,” said Henrik Balle Boysen, executive director of HAEi, the international organization for the world’s HAE patient groups, in a Shire press release. “Clinical work to bring treatment options to younger patients is vitally important and greatly appreciated by the global HAE community.”
According to Shire, an open label, non-randomized, single-arm study involving 32 pediatric HAE patients was conducted, with more than 70% of patients experienced symptom relief at 1.1 hours, and more than 90% by 2 hours after being treated with the drug.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.